BioSyent Stock

BioSyent Net Margin

The Net Profit Margin of BioSyent (RX.V) as of Sep 11, 2026 is 20.93 %. In the previous year, Net Profit Margin was 20.75 % — a change of 0.87% (higher).

Net Margin

20.93 %

YoY

0.87%

Last updated:

Net Profit Margin of BioSyent is 2026 20.93 % . Net Profit Margin of BioSyent was 2025 20.75 % . It decreases by 0.87% higher compared to the previous year.

BioSyent's net margin stands at 20.9%, down from 21.9% several years earlier.

The BioSyent Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
26.50 CAD
Jan 1, 2019
20.39 CAD
Jan 1, 2020
16.99 CAD
Jan 1, 2021
21.95 CAD
Jan 1, 2022
19.55 CAD
Jan 1, 2023
20.45 CAD
Jan 1, 2024
20.75 CAD
Jan 1, 2025
20.93 CAD
The BioSyent Net Margin history
YEARNet MarginYoY
20.93 %+0.87%
20.75 %+1.49%
20.45 %+4.62%
19.55 %-10.95%
21.95 %+29.15%
16.99 %-16.67%
20.39 %-23.05%
26.50 %+5.70%
25.08 %+4.28%
24.05 %-1.72%
24.47 %-5.28%
25.83 %+10,348.79%
0.25 %-19.42%
0.31 %+104.96%
0.15 %+382.43%
0.03 %-112.26%
-0.25 %-3.16%
-0.26 %+128.99%
-0.11 %-145.10%
0.25 %
Access this data via the Eulerpool API

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

Net Profit Margin of BioSyent is 20.93 % in 2026.

Net Profit Margin of BioSyent changed from 20.75 % to 20.93 %, representing a 0.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin BioSyent since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's BioSyent with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — BioSyent

All Key Metrics — BioSyent